Halozyme Therapeutics, Inc.
HALO · Healthcare
$107.72
Indlæser diagram…
Nyheder
Seneste overskrifter for denne aktie
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
Acumen Pharmaceuticals announced that management will participate in two upcoming investor conferences in September 2026: the Cantor Global Healthcare Conference on September 9 and Citi's 2026 Biopharma Back to School Conference on September 10. The company is advancing its lead candidate sabirnetug (ACU193) in Phase 2 trials for early symptomatic Alzheimer's disease and expects to report topline results in late 2026.
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now
A $1,000 investment in Halozyme Therapeutics made in September 2016 would be worth $10,866.33 as of September 1, 2026, representing a 986.63% gain. The biopharmaceutical company's success is driven by its ENHANZE drug delivery technology licensed to major pharma partners like Roche, Takeda, J&J, and AbbVie, generating royalties that comprise over 55% of revenues. While strong demand for partnered drugs and new collaboration deals support growth, biosimilar competition for blockbuster drugs and dependence on partner revenues present risks.